EUS-guided therapies for primary and secondary prophylaxis in gastric varices-An updated systematic review and meta-analysis

EUS引导下治疗胃静脉曲张一级和二级预防——最新系统评价和荟萃分析

阅读:1

Abstract

BACKGROUND AND OBJECTIVES: Gastric varices (GVs) are associated with a higher risk of uncontrolled bleeding and death when compared with esophageal varices. While endoscopic glue injection therapy has been traditionally used for secondary prophylaxis in GV, data regarding primary prophylaxis continue to emerge. Recently, EUS-guided therapies have been used in GV bleeding. METHODS: We conducted a comprehensive search of several major databases from inception to June 2022. Our primary goals were to estimate the pooled rates of treatment efficacy, GV obliteration, GV recurrence, and rebleeding with EUS-guided therapy in primary and secondary prophylaxis. Overall adverse events and technical failures were assessed. Random-effects model was used for our meta-analysis, and heterogeneity was assessed using the I(2) % statistics. RESULTS: Eighteen studies with 604 patients were included. In primary prophylaxis, pooled rate of GV obliteration was 90.2% (confidence interval [CI], 81.1-95.2; I(2) = 0). With combination EUS-glue and coil therapy, the rate was 95.4% (CI, 86.7%-98.5%; I(2) = 0). Pooled rate of posttherapy GV bleeding was 4.9% (CI, 1.8%-12.4%; I(2) = 0). In secondary prophylaxis, pooled rate of treatment efficacy was 91.9% (CI, 86.8%-95.2%; I(2) = 12). With EUS-glue, EUS-coil, and combination EUS-glue and coil, the rates were 94.3% (CI, 88.9%-97.1%; I(2) = 0), 95.5% (CI, 80.3%-99.1%; I(2) = 0), and 88.7% (CI, 76%-95.1%; I(2) = 14), respectively. Pooled rate of GV obliteration was 83.6% (CI, 71.5%-91.2%; I(2) = 74). With EUS-glue, EUS-coil, and combination EUS-glue and coil, the rates were 84.6% (CI, 75.9%-90.6%; I(2) = 31), 92.3% (CI, 81.1%-97.1%; I(2) = 0), and 84.5% (CI, 50.8%-96.7%; I(2) = 75), respectively. Pooled rates of GV rebleeding and recurrence were 18.1% (CI, 13.1%-24.3%; I(2) = 16) and 20.6% (CI, 9.3%-39.5%; I(2) = 66), respectively. CONCLUSION: Our analysis shows that EUS-guided therapy for GVs is technically feasible and clinically successful in both primary and secondary prophylaxis of GV.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。